By becoming more international in scope and publishing excellent articles, we believe that the Journal soon will be listed in the Index Medicus, and its citation rates and upcoming impact factor will rise. We plan to be more discrete in selecting the papers we publish. The Korean Journal of Pathology is currently rejecting 15-20% of articles. Although it is one of the most difficult jobs for editors to discriminate precious results of hard-working researchers, it appears to be inevitable that the rejection rate be raised, considering the increasing amount of submissions. On the other side, we will strive to be assured of the quality of peer review and editing decisions. With operating the new review system, the speed and validity of peer review will be observed by 'editors-in-charge' from subspecialty fields. Editorial policies and responsibility will precede editorial freedom and privilege. We will also continue to maintain high standards of ethics in writing and publishing.
It is true that it burdens me to take over this position at this critical time, but I look forward to working with my co Editorin-Chief, Dr. So-Young Jin, and the editorial board to pursue and watch the continual progress of the Korean Journal of Pathology. As always, we thank all readers, authors, and especially for unseen contributions of reviewers and editorial staffs.
